Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Directors Deals Ltd.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Chongqing Lummy Pharmaceutical obtains GMP permit


Tuesday, 1 Apr 2014 08:00pm EDT 

Chongqing Lummy Pharmaceutical Co Ltd:Obtained a goods manufacturing practice (GMP) permit from Chongqing Food and Drug Administration, for bulk drug (esomeprazole) with valid period until March 30, 2019 and capsule with valid period until March 4, 2019. 

Company Quote

49.1
-2.89 -5.56%
24 Apr 2015